Results 41 to 50 of about 10,061 (158)
British Journal of Haematology, EarlyView.Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê +3 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 Background Few studies have examined how antiplatelet therapies are selected during the routine care of acute myocardial infarction patients, particularly relative to the patient's estimated mortality and bleeding risks.
Amit N. Vora +10 more
doaj +1 more source
Атеротромбоз, 2018 Prasugrel is a third-generation thienopyridine that provides earlier onset of action, has a reduced probability of insensitivity to the drug, a greater degree of inhibition of ADP-induced platelet aggregation compared to clopidogrel.
O. O. Shakhmatova, A. L. Komarov
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Aims: In this pre-specified analysis of the “endothelium, stent and antiplatelet therapy” study, we investigate the impact of antiplatelet therapies on microvascular function in patients undergoing stenting for an acute coronary syndrome.Methods and ...
Boris Schnorbus +7 more
doaj +1 more source
The potential for biased signalling in the P2Y receptor family of GPCRs
British Journal of Pharmacology, EarlyView.The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk +2 more
wiley +1 more source
Health Technology Assessment, 2015 Background: Acute coronary syndromes (ACSs) are life-threatening conditions associated with acute myocardial ischaemia. There are three main types of ACS: ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (
Janette Greenhalgh +9 more
doaj +1 more source
Prasugrel for the treatment of patients with acute coronary syndrome
Vascular Health and Risk Management, 2009 Filippo Marzot, Vittorio PengoClinical Cardiology, Thrombosis Centre, University of Padua, ItalyAbstract: Prasugrel (CS-747, LY640315) is a novel member of the thienopyridine class of oral anti-platelet agents (also including ticlopidine and clopidogrel).
Filippo Marzot, Vittorio Pengo
doaj
Safety of Prasugrel in Indian patients – Multicentric registry of 1000 cases
Indian Heart Journal, 2014 Background: Clopidogrel has been the only available antiplatelet drug used along with aspirin in patients of ACS. In recent years 2 new antiplatelet drugs (Prasugrel and Ticagrelor) have become available.
Upendra Kaul +14 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao +8 more
wiley +1 more source
PLoS ONE, 2015 BackgroundPrasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes. Data available on prasugrel reloading in clopidogrel treated patients with high residual platelet reactivity (HRPR) i.e. poor responders,
Tobias Geisler +14 more
doaj +1 more source